Plandai Biotech Stock Performance
| PLPL Stock | USD 0.0001 0.00 0.00% |
Plandai Biotech holds a performance score of 16 on a scale of zero to a hundred. The company holds a Beta of 28.71, which implies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Plandai Biotech will likely underperform. Use Plandai Biotech market risk adjusted performance, information ratio, as well as the relationship between the Information Ratio and rate of daily change , to analyze future returns on Plandai Biotech.
Risk-Adjusted Performance
Solid
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Plandai Biotech are ranked lower than 16 (%) of all global equities and portfolios over the last 90 days. Despite quite weak basic indicators, Plandai Biotech disclosed solid returns over the last few months and may actually be approaching a breakup point. ...more
Plandai |
Plandai Biotech Relative Risk vs. Return Landscape
If you would invest 0.00 in Plandai Biotech on November 1, 2025 and sell it today you would earn a total of 0.01 from holding Plandai Biotech or generate 9.223372036854776E16% return on investment over 90 days. Plandai Biotech is currently generating 46.6667% in daily expected returns and assumes 221.2956% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than Plandai, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Plandai Biotech Target Price Odds to finish over Current Price
The tendency of Plandai Pink Sheet price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 0.0001 | 90 days | 0.0001 | about 38.97 |
Based on a normal probability distribution, the odds of Plandai Biotech to move above the current price in 90 days from now is about 38.97 (This Plandai Biotech probability density function shows the probability of Plandai Pink Sheet to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days the pink sheet has the beta coefficient of 28.71 indicating as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Plandai Biotech will likely underperform. In addition to that Plandai Biotech has an alpha of 45.1837, implying that it can generate a 45.18 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta). Plandai Biotech Price Density |
| Price |
Predictive Modules for Plandai Biotech
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Plandai Biotech. Regardless of method or technology, however, to accurately forecast the pink sheet market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the pink sheet market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Plandai Biotech Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Plandai Biotech is not an exception. The market had few large corrections towards the Plandai Biotech's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Plandai Biotech, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Plandai Biotech within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 45.18 | |
β | Beta against Dow Jones | 28.71 | |
σ | Overall volatility | 0.000025 | |
Ir | Information ratio | 0.21 |
Plandai Biotech Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Plandai Biotech for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Plandai Biotech can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Plandai Biotech is way too risky over 90 days horizon | |
| Plandai Biotech has some characteristics of a very speculative penny stock | |
| Plandai Biotech appears to be risky and price may revert if volatility continues | |
| Plandai Biotech has high likelihood to experience some financial distress in the next 2 years | |
| Plandai Biotech currently holds 50.53 K in liabilities with Debt to Equity (D/E) ratio of 0.95, which is about average as compared to similar companies. Plandai Biotech has a current ratio of 0.01, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Plandai Biotech until it has trouble settling it off, either with new capital or with free cash flow. So, Plandai Biotech's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Plandai Biotech sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Plandai to invest in growth at high rates of return. When we think about Plandai Biotech's use of debt, we should always consider it together with cash and equity. | |
| The entity reported the previous year's revenue of 411.99 K. Net Loss for the year was (4.01 M) with loss before overhead, payroll, taxes, and interest of (768.91 K). | |
| Plandai Biotech currently holds about 7.96 K in cash with (1.1 M) of positive cash flow from operations. |
Plandai Biotech Fundamentals Growth
Plandai Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Plandai Biotech, and Plandai Biotech fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Plandai Pink Sheet performance.
| Return On Asset | -0.21 | |||
| Operating Margin | (12.22) % | |||
| Current Valuation | 236.87 K | |||
| Shares Outstanding | 263.19 M | |||
| Price To Earning | (0.32) X | |||
| Price To Sales | 1.04 X | |||
| Revenue | 411.99 K | |||
| EBITDA | (2.1 M) | |||
| Cash And Equivalents | 7.96 K | |||
| Total Debt | 50.53 K | |||
| Debt To Equity | 0.95 % | |||
| Book Value Per Share | (0.05) X | |||
| Cash Flow From Operations | (1.1 M) | |||
| Earnings Per Share | (0.03) X | |||
| Total Asset | 6.82 M | |||
| Retained Earnings | (39.32 M) | |||
| Current Asset | 176 K | |||
| Current Liabilities | 15.44 M | |||
About Plandai Biotech Performance
By examining Plandai Biotech's fundamental ratios, stakeholders can obtain critical insights into Plandai Biotech's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Plandai Biotech is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
Planda Biotechnology, Inc. focuses on the production of proprietary botanical extracts for the nutriceutical and pharmaceutical industries. Planda Biotechnology, Inc. is based in London, the United Kingdom. Diamond Ranch is traded on OTC Exchange in the United States.Things to note about Plandai Biotech performance evaluation
Checking the ongoing alerts about Plandai Biotech for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Plandai Biotech help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Plandai Biotech is way too risky over 90 days horizon | |
| Plandai Biotech has some characteristics of a very speculative penny stock | |
| Plandai Biotech appears to be risky and price may revert if volatility continues | |
| Plandai Biotech has high likelihood to experience some financial distress in the next 2 years | |
| Plandai Biotech currently holds 50.53 K in liabilities with Debt to Equity (D/E) ratio of 0.95, which is about average as compared to similar companies. Plandai Biotech has a current ratio of 0.01, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Plandai Biotech until it has trouble settling it off, either with new capital or with free cash flow. So, Plandai Biotech's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Plandai Biotech sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Plandai to invest in growth at high rates of return. When we think about Plandai Biotech's use of debt, we should always consider it together with cash and equity. | |
| The entity reported the previous year's revenue of 411.99 K. Net Loss for the year was (4.01 M) with loss before overhead, payroll, taxes, and interest of (768.91 K). | |
| Plandai Biotech currently holds about 7.96 K in cash with (1.1 M) of positive cash flow from operations. |
- Analyzing Plandai Biotech's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Plandai Biotech's stock is overvalued or undervalued compared to its peers.
- Examining Plandai Biotech's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Plandai Biotech's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Plandai Biotech's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Plandai Biotech's pink sheet. These opinions can provide insight into Plandai Biotech's potential for growth and whether the stock is currently undervalued or overvalued.
Other Information on Investing in Plandai Pink Sheet
Plandai Biotech financial ratios help investors to determine whether Plandai Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Plandai with respect to the benefits of owning Plandai Biotech security.